Results of the phase 3 EXPAND trial suggest that siponimod may help fill the void of useful therapies for patients with secondary progressive multiple sclerosis.
Cleveland Clinic Florida Colorectal Chairman Steven Wexner, MD, discusses sacral neuromodulation’s role in patients who have had rectal extirpation followed by neorectal reconstruction.
Obtaining fluid intake and output is part of basic patient care, but it can be overlooked when nurses are busy. Med-surg nurses at Cleveland Clinic’s Fairview Hospital created a simulation to show the importance of I&Os.
Physicians and other healthcare leaders from all over the world are craving the kind of industry-specific knowledge that will enable them to lead the future of healthcare and meet the challenges of a tumultuous environment. We offer several external programs for clinicians and non-clinicians alike based on the success of our internal programs and led by Cleveland Clinic leaders that help bridge the gap between clinical expertise and business leadership.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Healthcare is a unique environment because of the high degrees of stress and burnout our physicians and providers can face. Because we are a physician-led organization, our leaders at the highest level understand the challenges clinicians face in the current healthcare environment.
Neurosurgeon Gene Barnett, MD, MBA, is the 2017 Sones Innovation Award honoree for inventing frameless neuronavigation and leading the development of laser thermal therapy for brain tumors.
Complex microsurgery procedure with lymphatic mapping may reduce risk of lymphedema following breast cancer surgery.
Quality of care should not be dictated by geography or socioeconomic status. Mary Alissa Willis, MD, says she’s excited about the ways that technology will help bridge this gap.
Robotic hernia repair is now an option for more patients. Ajita Prabhu, MD, explains.
This randomized phase 3 study compared treatment with sunitibib with a combination therapy of the anti-VEGF drug bevacizumab and atezolizumab, an engineered monoclonal antibody against PD-L1.